Hysteroscopic Findings in Women Using Progesterone Only Pills (Minipills)
NCT ID: NCT05024604
Last Updated: 2021-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
140 participants
OBSERVATIONAL
2021-09-01
2022-12-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Value of Oral Micronized Progesterone in the Prevention of Spontaneous Preterm Birth
NCT02571296
Abnormal Uterine Bleeding and Progestin-only Contraceptives
NCT03398811
LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia
NCT04385667
Metabolism of 0.35mg Norethindrone vs 5mg Norethindrone Acetate
NCT05294341
Assessing Use Of Mifepristone After Progestin Priming For Use As "Missed Period Pills"
NCT04676776
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
When performing diagnostic hysteroscopic procedures, it is best if a non-viscous, physiologic solution is used i.e. Saline or Lactated Ringers as opposed to CO2 gas. CO2 is commonly used for diagnostic hysteroscopy but is difficult to use in the presence of blood or mucous. Adequate distention pressures (50-70 mmHG) can be achieved in the office by the use of gravity or a pressure bags. Most office based procedures are of short duration and no more than 2 liters of solution should be utilized. In this situation, it is not necessary to monitor fluid inflow, outflow and deficits in the office setting. The standard access approach to the cervix involves placing a speculum within the vagina (preferably side opening), placing single tenaculum on the anterior lip of the cervix, injecting the cervix with local anaesthesia (if necessary), and placing the rigid continuous flow hysteroscope within the cervical canal. In most patients, including nulliparous and post menopausal patients, it is not necessary to dilate the cervix prior to insertion. Once the hysteroscope is within the cervical canal, the speculum should be removed, the fluid flow is begun and the hysteroscope is advanced through the cervical canal and into the uterine cavity under direct visualization.
The endometrium will be inspected by outpatient hysteroscopy The following observations made at hysteroscopy, and reviewed in detail from the video record of the examination Glandular and stromal changes The color, thickness, texture and regularity of the endometrial stroma would be assessed during hysteroscopy Superficial vascular density Endometrial vascular density would be assessed at hysteroscopy by direct inspection of the blood vessels, and graded according to the abundance of superficial vessels observed. Superficial vascular density would be reassessed after uterine collapse and Re distention.
Vascular morphology The shape and configuration of superficial and deep endometrial vessels would be assessed at hysteroscopy. The presence of regular and irregular (neo vascular and mosaic) vascular patterns in superficial and deep vessels would be recorded and graded. The presence of petechiae and ecchymosis would be recorded.
All the above values were regraded after collapse and re distention of the uterus, provided that a clear view of the endometrium could be obtained.
Vascular distribution The distribution of superficial and deep vasculature in the endometrium would be inspected and graded as even' or 'patchy'.
Endometrial biopsies biopsies would be taken at each hysteroscopy. A small amount of endometrial tissue was obtained under direct vision using the biopsy curette (novak curette). also a detailed comment by the examiner would be given regarding the uterine ostium of the fallopian tube \& any changes in the cervical canal and the cervical secretions any abnormal findings or pathology would be mentioned also .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
study group
women receiving mini pills as a method of contraception with symptoms not diagnosed with us
Progesterone Only Product in Oral Dose Form
mini pills as a contraceptive method
office hysterscopy
office hysteroscoy
Control group
women attending to office hysteroscopy unit and not taking hormonal therapy
office hysterscopy
office hysteroscoy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Progesterone Only Product in Oral Dose Form
mini pills as a contraceptive method
office hysterscopy
office hysteroscoy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* women using POP.
* Age: reproductive age.
* Symptoms: abnormal uterine bleeding without an organic cause.
2-Authorization to participate in the study .
* Control group
1- women attending to office hysteroscopy clinic
* Age: reproductive Age
* Contraception use : none.
* Hormonal use: none.
* Symptoms: abnormal uterine bleeding without an organic cause. All women in both groups would be subjected to Trans Vaginal U.S before doing hysteroscopy .
Exclusion Criteria
* Coagulopathies
* Any contraindications to POPs as :
* past or current breast cancer, cirrhosis, and use of anticonvulsants
* suspected pregnancy
* current stroke or IHD
* severe hypertension
•Any contraindications to hysteroscopy as :
* Pelvic infection
* Pregnancy
* Cervical cancer
* Heavy uterine bleeding.
* Control group --Women using any type of hormones including COCs .
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samuel Gendy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Samuel Gendy
Resident of Obstetrics & Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Women health hospital , Assuit university
Asyut, Assuit, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
117101333
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.